StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.94 | $0.98 | +3.83% | 0.2M |
| 05-19 | $0.98 | $0.95 | -3.06% | 0.0M |
| 05-20 | $0.96 | $0.97 | +0.80% | 0.0M |
| 05-21 | $0.97 | $0.99 | +1.86% | 0.1M |
| 05-22 | $0.98 | $0.99 | +1.33% | 0.0M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.